Chronic Rosiglitazone Therapy Normalizes Expression of ACE1, SCD1 and other Genes in the Kidney of Obese Zucker Rats as Determined by Microarray Analysis

Abstract

Thiazolidinediones increase tissue insulin sensitivity and are protective against worsening of nephropathy and hypertension in diabetes. Mechanisms underlying protection at the renal level likely involve a variety of unknown changes in gene expression. We examined kidney gene expression in obese and lean Zucker rats in response to rosiglitazone (Avandia^®), a peroxisome proliferator activated receptor (γ-subtype) agonist. Lean and obese Zucker rats were treated with either control chow or chow with added rosiglitazone (3 mg/kg·bw) for 12 weeks (n=3/group). Total kidney mRNA expression was evaluated using the Affymetrix Rat Genome 230 2.0 GeneChip. 903 probe sets were significantly (P<0.05) altered with at least 1.5-fold changes between groups. In untreated obese rats, 300 probe sets were increased and 244 decreased, relative to lean. Increased genes included the β-subunit of the epithelial sodium channel (ENaC), the thiazide-sensitive Na-Cl cotransporter, and aquaporin 3. Decreased genes included angiotensin converting enzyme, type 1 (ACE1). FatiGO analysis showed that the highest number of altered genes between lean and obese belonged to the categories: ion binding, hydrolase activity, and protein binding. RGZ increased expression of uncoupling protein 1 (UCP1), CD36, and fatty acid binding protein 4 (FAbp4) in both lean and obese rats. In obese rats, 33 genes were normalized by RGZ (no longer different from lean) including ACE1, fatty acid synthase (Fasn), and stearoyl-coenzyme A desaturase (SCD1). Ingenuity Pathways System analysis of genes upregulated by RGZ in obese rats revealed two major nodes affected: PPAR-γ and tumor necrosis factor α (TNF-α).

Key words

thiazolidinediones - PPAR-γ agonists - renal - type II diabetes - obesity

References

• 1 Affymetrix . Data Sheet: Gene Chip Rat Genome 230 Arrays. 2005; 
• 2 Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats.  Nat Genet. 1999;  21 76-83
• 3 Alonso-Galicia M, Brands MW, Zappe DH, Hall JE. Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity.  Hypertension. 1996;  28 1047-1054
• 4 Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, Vidal H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients.  Diabetes. 1997;  46 1319-1327
• 5 Becker M, Umrani D, Lokhandwala MF, Hussain T. Increased renal angiotensin II AT1 receptor function in obese Zucker rat.  Clin Exp Hypertens. 2003;  25 35-47
• 6 Bhatia V, Viswanathan P. Insulin resistance and PPAR insulin sensitizers.  Curr Opin Investig Drugs. 2006;  7 891-897
• 7 Bickel CA, Verbalis JG, Knepper MA, Ecelbarger CA. Increased renal Na-K-ATPase, NCC, and beta-ENaC abundance in obese Zucker rats.  Am J Physiol Renal Physiol. 2001;  281 F639-648
• 8 Casarini DE, Boim MA, Stella RC, Krieger-Azzolini MH, Krieger JE, Schor N. Angiotensin I-converting enzyme activity in tubular fluid along the rat nephron.  Am J Physiol. 1997;  272 F405-409
• 9 Chen L, Yang B, MacNulty JA, Clifton LG, Binz JG, Grimes AM, Strum JC, Harrington WW, Chen Z, Balon TW, Stimpson SA, Brown KK. GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats.  J Pharmacol Exp Ther. 2005;  312 718-725
• 10 Day C. Thiazolidinediones: a new class of antidiabetic drugs.  Diabet Med. 1999;  16 179-192
• 11 Deak F, Wagener R, Kiss I, Paulsson M. The matrilins: a novel family of oligomeric extracellular matrix proteins.  Matrix Biol. 1999;  18 55-64
• 12 Ecelbarger CA, Kim GH, Terris J, Masilamani S, Mitchell C, Reyes I, Verbalis JG, Knepper MA. Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney.  Am J Physiol Renal Physiol. 2000;  279 F46-53
• 13 Ecelbarger CA, Knepper MA, Verbalis JG. Increased abundance of distal sodium transporters in rat kidney during vasopressin escape.  J Am Soc Nephrol. 2001;  12 207-217
• 14 Erdely A, Freshour G, Maddox DA, Olson JL, Samsell L, Baylis C. Renal disease in rats with type 2 diabetes is associated with decreased renal nitric oxide production.  Diabetologia. 2004;  47 1672-1676
• 15 Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.  Exp Clin Endocrinol Diabetes. 2000;  108 151-163
• 16 Fujiwara K, Hayashi K, Matsuda H, Kubota E, Honda M, Ozawa Y, Saruta T. Altered pressure-natriuresis in obese Zucker rats.  Hypertension. 1999;  33 1470-1475
• 17 Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.  Nat Med. 2005;  11 861-866
• 18 Guan Y, Zhang Y, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans.  Am J Physiol. 1997;  273 F1013-1022
• 19 Guan Y, Zhang Y, Schneider A, Davis L, Breyer RM, Breyer MD. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature.  Am J Physiol Renal Physiol. 2001;  281 F1036-1046
• 20 Harker CT, O'Donnell MP, Kasiske BL, Keane WF, Katz SA. The renin-angiotensin system in the type II diabetic obese Zucker rat.  J Am Soc Nephrol. 1993;  4 1354-1361
• 21 Hirsch IB, Kelly J, Cooper S. Pulmonary edema associated with troglitazone therapy.  Arch Intern Med. 1999;  159 1811
• 22 Hong G, Lockhart A, Davis B, Rahmoune H, Baker S, Ye L, Thompson P, Shou Y, O'Shaughnessy K, Ronco P, Brown J. PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells.  Faseb J. 2003;  17 1966-1968
• 23 Houseknecht KL, Cole BM, Steele PJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review.  Domest Anim Endocrinol. 2002;  22 1-23
• 24 Huang X, Birk DE, Goetinck PF. Mice lacking matrilin-1 (cartilage matrix protein) have alterations in type II collagen fibrillogenesis and fibril organization.  Dev Dyn. 1999;  216 434-441
• 25 Idris I, Gray S, Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability.  Diabetologia. 2003;  46 288-290
• 26 Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data.  Biostatistics. 2003;  4 249-264
• 27 Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats.  Diabetes. 2000;  49 1022-1032
• 28 Jezek P, Garlid KD. Mammalian mitochondrial uncoupling proteins.  Int J Biochem Cell Biol. 1998;  30 1163-1168
• 29 Kaestner KH, Ntambi JM, Kelly Jr TJ, Lane MD. Differentiation-induced gene expression in 3T3-L1 preadipocytes. A second differentially expressed gene encoding stearoyl-CoA desaturase.  J Biol Chem. 1989;  264 14755-14761
• 30 Khan O, Riazi S, Hu X, Song J, Wade JB, Ecelbarger CA. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone.  Am J Physiol Renal Physiol. 2005;  289 F442-450
• 31 Kim GH, Masilamani S, Turner R, Mitchell C, Wade JB, Knepper MA. The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein.  Proc Natl Acad Sci USA. 1998;  95 14552-14557
• 32 Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).  J Biol Chem. 1995;  270 12953-12956
• 33 Lenhard JM. PPAR gamma/RXR as a molecular target for diabetes.  Receptors Channels. 2001;  7 249-258
• 34 Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.  Kidney Int. 2001;  59 1899-1910
• 35 Markovich D, Aronson PS. Specificity and regulation of renal sulfate transporters.  Annu Rev Physiol. 2006; 
• 36 Martens FM, Visseren FL, Lemay J, Koning EJ de, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones.  Drugs. 2002;  62 1463-1480
• 37 Masilamani S, Kim GH, Mitchell C, Wade JB, Knepper MA. Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney.  J Clin Invest. 1999;  104 R19-23
• 38 Miyazaki M, Ntambi JM. Role of stearoyl-coenzyme A desaturase in lipid metabolism.  Prostaglandins Leukot Essent Fatty Acids. 2003;  68 113-121
• 39 Riazi S, Khan O, Hu X, Ecelbarger C. Aldosterone infusion with high-NaCl diet increases blood pressure in obese but not lean Zucker rats.  Am J Physiol Renal Physiol. 2006; 
• 40 Riazi S, Khan O, Tiwari S, Hu X, Ecelbarger CA. Rosiglitazone Regulates ENaC and Na-K-2Cl Cotransporter (NKCC(2)) Abundance in the Obese Zucker Rat.  Am J Nephrol. 2006;  26 245-257
• 41 Rocchi S, Auwerx J. Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator.  Ann Med. 1999;  31 342-351
• 42 Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats.  J Pharmacol Exp Ther. 2004;  308 426-433
• 43 Takano H, Komuro I. Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease.  J Diabetes Complications. 2002;  16 108-114
• 44 Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone.  Ann Pharmacother. 2001;  35 123-124
• 45 Tiwari S, Blasi ER, Hu X, Heyen J, Ecelbarger CA. Blood pressure, ENaC, and sgk-1 regulation in Sprague-Dawley rats after short-term administration of high-dose PPAR agonists.  J Am Soc Nephrol. 2005;  165 566A , (Abstract)
• 46 Tiwari S, Packer RK, Hu X, Sugimura Y, Verbalis JG, Ecelbarger CA. Increased renal {alpha}-ENaC and NCC abundance and elevated blood pressure are independent of hyperaldosteronism in vasopressin escape.  Am J Physiol Renal Physiol. 2006; 
• 47 Zwieten PA Van, Kam KL, Pijl AJ, Hendriks MG, Beenen OH, Pfaffendorf M. Hypertensive diabetic rats in pharmacological studies.  Pharmacol Res. 1996;  33 95-105
• 48 Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.  Diabetes. 1999;  48 1448-1453
• 49 Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.  Diabetes. 1998;  47 810-814
• 50 Xu ZG, Lanting L, Vaziri ND, Li Z, Sepassi L, Rodriguez-Iturbe B, Natarajan R. Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade.  Circulation. 2005;  111 1962-1969
• 51 Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius 3rd FC, Schnermann JB, Briggs JP. Expression of peroxisomal proliferator-activated recep-tors and retinoid X receptors in the kidney.  Am J Physiol. 1999;  277 F966-973

Correspondence